앵커 1

Communication

Nov 20, 2022

Prof. Jae-Hyung Park and Dong-kyu Cho selected as regular members of KAST

The Korean Academy of Science and Technology announced on the 20th that it had elected 28 full members for the year 2023 at the '2022 2nd...

Sep 27, 2022

The 'stem cell' challenge continues in the 'osteoarthritis' treatment market

[Medigate News Reporter Seo Min-ji] Although the number of patients with degenerative arthritis increases worldwide every year due to the...

Apr 21, 2022

Exostemtech applied for phase 1 clinical trial IND in Korea for an exosome-based osteoarthritis trea

"EST-P-EXO1" aims to regenerate damaged cartilage tissue and suppress pain Bio-venture Exostemtech has applied for the domestic clinical...

Jan 6, 2022

Daewoong Pharmaceutical and ExostemTech, joint development agreement for exosome treatment

Daewoong's 'DW-MSC' exosome extraction, purification and joint development of new indications Daewoong Pharmaceutical will join hands...

Nov 19, 2021

[Jump-Up Bio] Exostemtech said, "The first clinical trial in Korea next year...He's even going to ge

[Anchor comment] Today's JumpUp Bio introduces Exostemtech, which develops stem cell exosome treatments. It aims to enter clinical trials...

Nov 14, 2021

"The strength of Exostemtech is…World-class exosome mass production, analysis, and quality managemen

[an interview, ceo] The "platform technology developing, producing some the natural add-on to the following some eksso eksso" joyongu...

Oct 26, 2021

Exostemtech, a "exosome treatment," attracts 10 billion won in series B investment (Korea economy)

Exostemtech, a bio-venture specializing in the development of exosome-based treatments, announced on the 26th that it has attracted 10...

Jul 19, 2021

Exostemtech, Cancer Exosome Inhibitor Clinical Full-scale (The Bell)

Exostemtech, a bio-venture specializing in the development of exosome-based treatments, will begin clinical trials using cancer exosome...

Jul 16, 2021

Exostemtech approved phase 1 and 2a clinical trials for combination of Kitruda and Exosome inhibitor

Exostemtech, a new drug developer, announced on the 16th that it has received approval from the Ministry of Food and Drug Safety for...